Osteoporosis Drugs Market (Bisphosphonates, Calcitonin, Rank Ligand Inhibitors, Parathyroid Hormone Therapy (PTH) and Selective Estrogen Receptor Modulators (SERMs)) for Male and Female Population: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021

Description

The report covers forecast and analysis for the osteoporosis drugs market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based revenue (USD Billion). The study includes drivers and restraints for the osteoporosis drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the osteoporosis drugs market on a global level.

In order to give the users of this report a comprehensive view on the osteoporosis drugs market, we have to include competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein drug class segments and gender segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new drug class launch, agreements, partnerships, collaborations & joint ventures, research& development, drug class and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, drug class portfolio of various companies along with patent analysis (2011-2016) bifurcated into the patent trend, patent share by company and patent analysis according to the region.

The study provides a decisive view on the osteoporosis drugs market by segmenting the market based on drug class, gender, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. Based on drug class the market is segmented into bisphosphonates, calcitonin, rank ligand inhibitors, parathyroid hormone therapy (PTH) and selective estrogen receptor modulators (SERMs). Key gender market covered under this study includes male and female. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and the Middle East & Africa with its further bifurcation into major countries including the U.S. Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for osteoporosis drugs based on individual drug class and gender in all the regions and countries.

The report also includes detailed profiles of end players such as Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc, and Teva Pharmaceutical Industries Ltd.

This report segments the global osteoporosis drugs market as follows:

Global Osteoporosis Drugs Market: Drug Class Segment Analysis

• Bisphosphonates
• Calcitonin 
• Rank Ligand Inhibitors
• Parathyroid Hormone Therapy (PTH) 
• Selective Estrogen Receptor Modulators (SERMs)

Global Osteoporosis Drugs Market: Gender Segment Analysis

• Male
• Female

Global Osteoporosis Drugs Market: Regional Segment Analysis

• North America
  • U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa

Table Of Content

• Chapter 1. Introduction
  • 1.1. Report description and scope
  • 1.2. Research scope
  • 1.3. Research methodology
    • 1.3.1. Market research process
    • 1.3.2. Market research methodology
• Chapter 2. Executive Summary
  • 2.1. Global osteoporosis drugs market, 2015 – 2021 (USD Billion)
  • 2.2. Global osteoporosis drugs market : Snapshot
• Chapter 3. Osteoporosis drugs – Market Dynamics
  • 3.1. Introduction
  • 3.2. Market drivers
    • 3.2.1. Global osteoporosis drugs market drivers: Impact analysis
    • 3.2.2. Increasing the prevalence of osteoporosis
  • 3.3. Market restraints
    • 3.3.1. Global osteoporosis drugs market restraints: Impact analysis
    • 3.3.2. Side effects of osteoporosis drugs
  • 3.4. Opportunities
    • 3.4.1. Advancement in Research and development
  • 3.5. Porter’s five forces analysis
    • 3.5.1. Bargaining power of suppliers
    • 3.5.2. Bargaining power of buyers
    • 3.5.3. Threat from new entrants
    • 3.5.4. Threat from new substitutes
    • 3.5.5. Degree of competition
  • 3.6. Market attractiveness analysis
    • 3.6.1. Market attractiveness analysis, by drug class segment
    • 3.6.2. Market attractiveness analysis, by gender segment
    • 3.6.3. Market attractiveness analysis, by regional segment
• Chapter 4. Global Osteoporosis drugs Market – Competitive Landscape
  • 4.1. Company Market Share Analysis(Subject to data availability)
    • 4.1.1. Global osteoporosis drugs market: company market share, 2015
  • 4.2. Strategic Development
    • 4.2.1. Acquisitions & Mergers
    • 4.2.2. New Drug class Launch
    • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
    • 4.2.4. Research and Development, Drug class and Regional Expansion
  • 4.3. Product Portfolio
  • 4.4. Patent Analysis (2011-2016)
    • 4.4.1. Patent Trend
    • 4.4.2. Patent Share by company
    • 4.4.3. By Region
• Chapter 5. Global Osteoporosis Drugs Market – Drug Class Segment Analysis
  • 5.1. Global osteoporosis drugs market: Drug class overview
    • 5.1.1. Global osteoporosis drugs market revenue share, by drug class, 2015 and 2021
  • 5.2. Bisphosphonates
    • 5.2.1. Global bisphosphonates market, 2015 – 2021(USD Billion)
  • 5.3. Electromagnetic Blood Flowmeters
    • 5.3.1. Global electromagnetic blood flowmeters market , 2015 – 2021(USD Billion)
  • 5.4. Rank Ligand Inhibitors
    • 5.4.1. Global rank ligand inhibitors market , 2015 – 2021(USD Billion)
  • 5.5. Parathyroid Hormone Therapy (PTH)
    • 5.5.1. Global parathyroid hormone therapy (PTH) market , 2015 – 2021(USD Billion)
  • 5.6. Selective Estrogen Receptor Modulators (SERMs)
    • 5.6.1. Global selective estrogen receptor modulators (SERMs) market , 2015 – 2021(USD Billion)
• Chapter 6. Global Osteoporosis Drugs Market – Gender Segment Analysis
  • 6.1. Global osteoporosis drugs market: Gender overview
    • 6.1.1. Global osteoporosis drugs market revenue share, by gender, 2015 and 2020
  • 6.2. Male
    • 6.2.1. Global osteoporosis drugs market for male, 2015 – 2021 (USD Billion)
  • 6.3. Female
    • 6.3.1. Global osteoporosis drugs market for female, 2015 – 2021(USD Billion)
• Chapter 7. Global Osteoporosis Drugs Market – Regional Segment Analysis
  • 7.1. Global osteoporosis drugs market: Regional overview
    • 7.1.1. Global osteoporosis drugs market revenue share, by region, 2015 and 2021
  • 7.2. North America
    • 7.2.1. North America osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
    • 7.2.2. North America osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
    • 7.2.3. U.S.
      • 7.2.3.1. U.S. osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
      • 7.2.3.2. U.S. osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
    • 7.3.2. Europe osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
      • 7.3.3.2. Germany osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
      • 7.3.4.2. France osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
    • 7.3.5. UK
      • 7.3.5.1. UK osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
      • 7.3.5.2. UK osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific osteoporosis drugs market revenue, by drug class, 2015 – 2021, (USD Billion)
    • 7.4.2. Asia Pacific osteoporosis drugs market revenue, by gender, 2015 – 2021, (USD Billion)
    • 7.4.3. China
      • 7.4.3.1. China osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
      • 7.4.3.2. China osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
    • 7.4.4. Japan
      • 7.4.4.1. Japan osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
      • 7.4.4.2. Japan osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
    • 7.4.5. India
      • 7.4.5.1. India osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
      • 7.4.5.2. India osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
    • 7.5.2. Latin America osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
    • 7.5.3. Brazil
      • 7.5.3.1. Brazil osteoporosis drugs market revenue, by drug class, 2015 – 2021(USD Billion)
      • 7.5.3.2. Brazil osteoporosis drugs market revenue, by gender, 2015 – 2021 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa osteoporosis drugs market revenue, by drug class, 2015 – 2021 (USD Billion)
    • 7.6.2. Middle East and Africa osteoporosis drugs market revenue, by gender, 2015 – 2021(USD Billion)
• Chapter 8. Company Profile
  • 8.1. Novartis International AG
    • 8.1.1. Overview
    • 8.1.2. Financials
    • 8.1.3. Product portfolio
    • 8.1.4. Business strategy
    • 8.1.5. Recent developments
  • 8.2. Eli Lilly Amgen Inc
    • 8.2.1. Overview
    • 8.2.2. Financials
    • 8.2.3. Product portfolio
    • 8.2.4. Business strategy
    • 8.2.5. Recent developments
  • 8.3. Forteo
    • 8.3.1. Overview
    • 8.3.2. Financials
    • 8.3.3. Product portfolio
    • 8.3.4. Business strategy
    • 8.3.5. Recent developments
  • 8.4. Merck & Co, Inc.
    • 8.4.1. Overview
    • 8.4.2. Financials
    • 8.4.3. Product portfolio
    • 8.4.4. Business strategy
    • 8.4.5. Recent developments
  • 8.5. Actavis plc
    • 8.5.1. Overview
    • 8.5.2. Financials
    • 8.5.3. Product portfolio
    • 8.5.4. Business strategy
    • 8.5.5. Recent developments
  • 8.6. Pfizer, Inc
    • 8.6.1. Overview
    • 8.6.2. Financials
    • 8.6.3. Product portfolio
    • 8.6.4. Business strategy
    • 8.6.5. Recent developments
  • 8.7. Teva Pharmaceutical Industries Ltd
    • 8.7.1. Overview
    • 8.7.2. Financials
    • 8.7.3. Product portfolio
    • 8.7.4. Business strategy
    • 8.7.5. Recent developments
  • 8.8. F. Hoffmann La Roche Ltd.
    • 8.8.1. Overview
    • 8.8.2. Financials
    • 8.8.3. Product portfolio
    • 8.8.4. Business strategy
    • 8.8.5. Recent developments

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Osteoporosis Drugs market. Zion Research has collected and analyzed key data belong to the global Osteoporosis Drugs market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Osteoporosis Drugs across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Osteoporosis Drugs industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

• Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
• Helps in validating and strengthening the secondary research findings
• Further, develops the analysis team’s expertise and market understanding
• Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

• Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
• Purchasing managers, technical personnel, distributors and resellers
• Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

• Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
• IDC and other relevant magazines
• Internal and external proprietary databases, and relevant patent and regulatory databases
• National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Osteoporosis Drugs market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

• Demographic data: Population split by segments
• Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
• Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
• Data is then cross-checked by an expert panel.

Free Analysis

Osteoporosis is a bone disease, which may be due to lower than normal peak bone mass and greater than the normal bone loss. Osteoporosis may also occur due to a number of diseases or treatments such as anorexia, hyperthyroidism, alcoholism, surgical removal of the ovaries, and kidney disease. As a result, bones become weak and may break from a fall or, in serious cases, from sneezing or minor bumps.  Until a broken bone occurs there are typically no symptoms. Osteoporosis drugs are a kind of medicine for osteoporosis, including Zoledronic Acid (Reclast or Zometa) Fosamax, Actonel, Boniva and others.

The major driving factor for the global osteoporosis market is rapidly growing the geriatric population of the world coupled with changing lifestyle is impinging bone health. Furthermore, increasing the prevalence of osteoporosis in postmenopausal women and increasing investment in drug discovery and development is further expected to fuel the market growth in the years to come. Prevalence of osteoporosis is more common with age. Around 15% of white people in their 50s and 70% of those over 80 are affected by osteoporosis diseases. However, there are several side effects of osteoporosis drugs such as irritable bowel syndrome, heartburn, nausea, and ulcers in the stomach. Thus, side effects of osteoporosis drugs are expected to hamper the market growth over the next few years. Nevertheless, increasing investment in R&D for advanced development of new drugs and classes are expected open up new growth avenues within the forecast period.

The osteoporosis drugs market is segmented on the basis of different drug classes such as bisphosphonates, calcitonin, rank ligand inhibitors, parathyroid hormone therapy (PTH) and selective estrogen receptor modulators (SERMs).  Osteoporosis drugs market was dominated by the bisphosphonates segment, which accounted for significant revenue share in 2015. Bisphosphonates are commonly prescribed the drug for treatment and prevention of osteoporosis disease. Thus, this segment is expected to show strong growth in the near future. Tele-monitoring is another growing segment of this market. Parathyroid hormone therapy (PTH) was another growing segment of this market. Parathyroid hormone therapy (PTH) was another key segment and it expected to witness significant growth in the near future. Development of new drug classes such as PTH and RANK ligand inhibitors are projected to fuel the growth of osteoporosis drug market over the forecast period. Pipeline products such as odanacatib (cathepsin K inhibitor) and romosozumab are awaiting the approval and may contribute to driving the market growth in the years to come.

Based on gender, the market can be segmented into male and female. Osteoporosis is more common in female than male. The female segment accounted for the largest share in 2015. Increasing the prevalence of osteoporosis in postmenopausal women is driving the growth of the market. There are wide discrepancies between the incidence rate in women and men. Moreover, about 90% of the hip fractures occur in people over 50 years old.

North America was the largest regional market led by the U.S. and is projected to witness the highest growth within the forecast period owing to high investments in the healthcare industry, surging R&D initiatives and accessibility to the excellent infrastructure. Asia Pacific osteoporosis drugs market is expected to be the fastest-growing region in the years to come. Growth in this region will be mainly driven by factors such as rising aged population and increasing patient’s awareness pertaining to bone health. Latin America and the Middle East & Africa are also expected to experience significant growth of osteoporosis market in the years to come.

Some of the key participants in osteoporosis drug market are Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc, and Teva Pharmaceutical Industries Ltd.  Major players are implementing sustainability strategies including product expansions, new product development and merger & acquisitions to gain the advantage over the competitors. For instance, drug maker Actavis Inc. agreed to acquire Warner Chilcott PLC for about USD5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specialty pharmaceutical brands—and shrinking its tax burden in 2013. Pipeline drugs of Merck and Pfizer cathepsin and aprela respectively are projected to provide the growth platform for these respective companies.